

# Accepted Manuscript

Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia

Rita Assi, Hagop Kantarjian, Nicholas J. Short, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Courtney DiNardo, Jan Burger, Jorge Cortes, Nitin Jain, William Wierda, Salim Chamoun, Marina Konopleva, Elias Jabbour

PII: S2152-2650(17)30840-6

DOI: [10.1016/j.clml.2017.08.101](https://doi.org/10.1016/j.clml.2017.08.101)

Reference: CLML 998

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 12 June 2017

Revised Date: 3 August 2017

Accepted Date: 10 August 2017

Please cite this article as: Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E, Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: [10.1016/j.clml.2017.08.101](https://doi.org/10.1016/j.clml.2017.08.101).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## **Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia**

Rita Assi<sup>1,\*</sup>, Hagop Kantarjian<sup>1</sup>, Nicholas J. Short<sup>1,\*</sup>, Naval Daver<sup>1</sup>, Koichi Takahashi<sup>1</sup>, Guillermo Garcia-Manero<sup>1</sup>, Courtney DiNardo<sup>1</sup>, Jan Burger<sup>1</sup>, Jorge Cortes<sup>1</sup>, Nitin Jain<sup>1</sup>, William Wierda<sup>1</sup>, Salim Chamoun<sup>1</sup>, Marina Konopleva<sup>1</sup>, Elias Jabbour<sup>1</sup>

<sup>1</sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

\* Equally contributed

**Short Title:** Blinatumomab and TKIs in patients with relapsed/refractory Ph+ leukemia

**Word count:** 1920

**Abstract word:** 240

**Keywords:** Blinatumomab; tyrosine kinase inhibitor; relapsed/refractory; Philadelphia chromosome; ALL; CML

### **Address Correspondence:**

Elias Jabbour, MD

Department of Leukemia

The University of Texas, M.D. Anderson Cancer Center

1515 Holcombe Blvd. Box 428. Houston, TX 77030

Phone: 713-792-4764; Fax: 713-794-4297; E-mail: [ejabbour@mdanderson.org](mailto:ejabbour@mdanderson.org)

Download English Version:

<https://daneshyari.com/en/article/8615877>

Download Persian Version:

<https://daneshyari.com/article/8615877>

[Daneshyari.com](https://daneshyari.com)